India Reports 1,134 New COVID-19 Cases In 24 Hours, The Highest So Far In 2023
COVID-19 cases in India continue to surge and in the past 24 hours, the country added 1,134 new infections.
This is the highest single-day increase in COVID-19 cases in India in 2023.?
Active cases cross 7,000
The 24-hour tally on Wednesday is nearly double the cases a day earlier when 699 infections were reported.?The COVID case tally was recorded at 4.46 crore (4,46,98,118).
With the increase of over a thousand new COVID-19 cases in the past 24 hours, the active caseload in India crossed the 7000 mark. According to Union Health Ministry data, the active caseload in India currently stands at 7,026, which is 0.01 per cent of total cases.
COVID-19 positivity rate
Meanwhile, the Daily Positivity rate has been reported to be 1.09 per cent, as the Weekly Positivity Rate in the country currently also stands at 0.98 per cent.
In the past 24 hours, the country has also reported five COVID-19 deaths, one each from Chhattisgarh, Delhi, Gujarat and Maharashtra and one reconciled by Kerala. The total COVID deaths in the country so far stand at 5,30,813.
83 COVID-19 cases in Delhi
On Wednesday, Delhi reported 83 new COVID-19 cases besides one death.
According to data from Delhi's Health department, the new cases took the overall case positivity rate in the national capital to 5.83 per cent.
"During the last 24 hours, 1423 swab samples were tested for COVID in Delhi and 83 new cases have been reported. A total of 21 patients were also deemed to have recovered today," a health official said.
Don't use antibiotics?for treatment?
With COVID-19 cases rising across the country, the Union Health Ministry has said that antibiotics should not be used for treatment unless there is clinical suspicion of bacterial infection.
According to the revised guideline for treating adult coronavirus patients, drugs such as Lopinavir-ritonavir, hydroxychloroquine, Ivermectin, Molnupiravir, Favipiravir, Azithromycin and Doxycycline should not be used for the treatment.
"Antibiotics should not be used unless there is clinical suspicion of bacterial infection. Possibility of co-infection of COVID-19 with other endemic infections must be considered," the guidelines said.
No evidence of benefit?
Additionally, in moderate or severe diseases at high risk of progression, Remdesivir may be considered for up to five days. It should be started within 10 days of symptoms onset in those with moderate to severe disease with a high risk of progression (requiring supplemental oxygen) but who are not on IMV or ECMO.
There is no evidence of benefit for the treatment of more than five days and it is not to be used in patients who are not on oxygen support or in the home setting.
Besides, Tocilizumab should be considered within 24-48 hours of the onset of severe disease/ICU admission in rapidly progressing moderate or severe disease.
For more on news and current affairs from around the world, please visit?Indiatimes News.
